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386Three-year results of the VIBRANT trial of
VIABAHN endoprosthesis versus bare nitinol stent
implantation for complex superﬁcial femoral artery
occlusive disease
Patrick J. Geraghty, MD,a Mark W. Mewissen, MD,b Michael R. Jaff, DO,c and Gary M. Ansel, MD,d
for the VIBRANT Investigators, Saint Louis, Mo; Milwaukee, Wisc; Boston, Mass; and Columbus, Ohio
Objective: The predominant mode of bare nitinol stent failure is diffuse in-stent restenosis, and failure rates correlate to
the length and complexity of the treated lesion. Addition of an expanded polytetraﬂuoroethylene lining to a nitinol stent
frame, as found in the VIABAHN endoprosthesis, mitigates the ingrowth of intimal hyperplasia. We compared the long-
term outcomes of complex superﬁcial femoral artery disease intervention using the VIABAHN endoprosthesis to those
obtained with bare nitinol stent implantation.
Methods: One hundred forty-eight patients with symptomatic complex superﬁcial femoral artery disease (TransAtlantic
Inter-Society Consensus I class C and D lesions, accompanied by intermittent claudication or ischemic rest pain) were
randomized to endovascular intervention using either bare nitinol stent implantation (76 patients) or nonheparin-bonded
VIABAHN endoprosthesis deployment (72 patients). Patency, limb hemodynamics, and quality of life were evaluated at
1, 6, 12, 24, and 36 months following intervention.
Results: The average treated lesion measured 18 6 8 cm in length, and 58.8% of lesions displayed segmental or complete
occlusion. At 3 years, primary patency rates (deﬁned by peak systolic velocity ratio #2.0 and no target lesion revascu-
larization) did not signiﬁcantly differ between patients treated with the VIABAHN stent graft and those who received
a bare nitinol stent (24.2% vs 25.9%; P [ .392). Stent fractures were signiﬁcantly more common in bare nitinol stents
(50.0%) than in the VIABAHN endoprostheses (2.6%). Primary-assisted patency rates were higher in those receiving bare
nitinol stents than the VIABAHN stent graft (88.8% vs 69.8%; P[ .04), although secondary patency rates did not differ
between bare nitinol stent and stent graft recipients (89.3% vs 79.5%; P[ .304). There were no instances of procedure-
related mortality or amputation. The hemodynamic improvement and quality measures improved equally in both groups.
Conclusions: The long-term outcomes of complex superﬁcial femoral artery disease intervention using the VIABAHN
endograft and bare nitinol stents are similar. Although primary patency rates are low in both study arms, excellent primary-
assisted and secondary patency rates were achieved, with sustained augmentation of limb perfusion and quality-of-life
measures. Patency rates diminish most rapidly in the ﬁrst year after device implantation. (J Vasc Surg 2013;58:386-95.)the Section of Vascular Surgery, Department of Surgery, Washington
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://dx.doi.org/10.1016/j.jvs.2013.01.050In 2005, the GORE VIABAHN [GORE and VIA-
BAHN are trademarks of W. L. Gore and Associates, Inc,
Flagstaff, Ariz] Endoprosthesis (W. L. Gore and Associates,
Flagstaff, Ariz) received United States Food and Drug
Administration (FDA) approval for treatment of symptom-
atic peripheral arterial disease of the superﬁcial femoral
artery (SFA). The TransAtlantic Inter-Society Consensus
(TASC) I writing group had previously established a classi-
ﬁcation scheme for infrainguinal occlusive disease (Table I)
and had provided recommendations regarding the choice
of endovascular or surgical management for each lesion
class. Endovascular intervention was favored for limited
TASC A lesions, whereas surgical revascularization was rec-
ommended for extensive TASC D obstructions. No
conclusive recommendations were made for the TASC B
and TASC C lesions.1
The TASC I recommendations notwithstanding, endo-
vascular treatment of complex SFA lesions became more
frequent in the subsequent years. Thus, at the 2005 incep-
tion of the GORE VIABAHN Endoprosthesis versus Bare
Nitinol Stent in the Treatment of Long Lesion ($8 cm)
Superﬁcial Femoral Artery Occlusive Disease (VIBRANT)
Table I. Morphologic lesion stratiﬁcationa
TASC I type A femoropopliteal lesion
Single stenosis <3 cm
TASC I type B femoropopliteal lesion
Single stenosis 3-10 cm length, not involving distal popliteal
Heavily calciﬁed stenoses up to 3 cm in length
Multiple lesions, each less than 3 cm (stenoses or occlusions)
TASC I type C femoropopliteal lesion
Single stenosis or occlusion longer than 5 cm
Multiple stenoses or occlusions, each 3-5 cm, without heavy
calciﬁcation
TASC I type D femoropopliteal lesion
Complete common femoral or SFA occlusions or complete
popliteal and proximal trifurcation occlusions
SFA, Superﬁcial femoral artery; TASC, TransAtlantic Inter-Society Consensus.
aAdapted from Dormandy JA, Rutherford RB. Management of peripheral
arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society
Consensus (TASC). J Vasc Surg 2000;31(1 Pt 2):S104.
Table II. Demographics and past medical history
VIABAHN
stent graft
Bare nitinol
stent P valuea
Number of randomized
subjects
72 76
Subject sex .865
No. (data available) 72 76
Male 45 (62.5%) 49 (64.5%)
Female 27 (37.5%) 27 (35.5%)
Subject ethnicity .714
No. (data available) 72 76
Hispanic or Latino 1 (1.4%) 3 (3.9%)
Not Hispanic or Latino 70 (97.2%) 71 (93.4%)
Unknown 1 (1.4%) 2 (2.6%)
Subject raceb
No. (data available) 72 76
American Indian or Alaska
Native
0 (0.0%) 0 (0.0%)
Asian 0 (0.0%) 2 (2.6%) .497
Black or African American 8 (11.1%) 9 (11.8%) 1.000
Native Hawaiian or Paciﬁc
Islander
0 (0.0%) 0 (0.0%)
White or Caucasian 63 (87.5%) 63 (82.9%) .493
Other race 1 (1.4%) 2 (2.6%) 1.000
Unknown race 0 (0.0%) 0 (0.0%)
Subject age, years .012
No. (data available) 72 76
Mean (SD) 69 (10) 64 (11)
Median 69 63
Range (45-90) (43-89)
Smoking status .357
Ever smoked 59 (81.9%) 67 (88.2%)
Never smoked 13 (18.1%) 9 (11.8%)
Diabetes 1.000
Insulin-dependent diabetic 11 (15.3%) 12 (15.8%)
Noninsulin-dependent
diabetic
20 (27.8%) 22 (28.9%)
Not diabetic 41 (56.9%) 42 (55.3%)
General medical history
Myocardial infarction 17 (23.6%) 19 (25.0%) .851
Hypertension 63 (87.5%) 58 (76.3%) .091
Dyslipidemia 52 (72.2%) 59 (77.6%) .456
Stroke 4 (5.6%) 7 (9.2%) .535
Chronic obstructive
pulmonary disease
9 (12.5%) 6 (7.9%) .420
Current treatment for
angina
2 (2.8%) 2 (2.6%) 1.000
Congestive heart failure 3 (4.2%) 8 (10.5%) .211
Previous PTA on study
limb >6 months ago
5 (6.9%) 4 (5.3%) .741
PTA, Percutaneous transluminal angioplasty; SD, standard deviation.
aP values for continuous measures based on Wilcoxon test with pooled
variances; for categorical variables on two-tailed Fisher exact test
(comparing VIABAHN stent graft and bare nitinol stent).
bSubjects may report multiple races.
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vascular treatment for TASC I class C and D SFA lesions.
Although virtually all of the bare nitinol stents deployed
in the femoropopliteal arteries lacked FDA-labeled indica-
tion for arterial use, these devices had gained substantial
clinical adoption for the treatment of complex SFA lesions.
Enthusiasm for this off-label use was somewhat tempered
by substantial loss of midterm patency.2 The primary
mode of bare nitinol stent patency loss was the ingrowth
of intimal hyperplasia through the stent interstices,
a process that appeared to be potentiated by nitinol stent
fractures in the mobile SFA territory.3 The microporous
polytetraﬂuoroethylene lining of the VIABAHN endopros-
thesis inhibits the development of in-stent restenosis, and
early clinical data suggested the potential of this device to
provide better patency rates than angioplasty in this chal-
lenging territory.4-6 A randomized, controlled trial com-
paring treatment with the VIABAHN endoprosthesis to
bare nitinol stents was therefore conducted.
METHODS
Investigational design and study inclusion. A total
of 19 medical centers in the United States were selected
for trial participation. Site primary investigators included
seven interventional cardiologists, six interventional radiolo-
gists, and six vascular surgeons. Participating vascular labo-
ratories had achieved accreditation from the Intersocietal
Commission for the Accreditation of Vascular Laboratories.
All ultrasound and radiographic examinations underwent
blinded, independent analysis by a duplex ultrasound
(DUS) core laboratory (VasCore, the Vascular Ultrasound
Core Laboratory, Massachusetts General Hospital, Boston,
Mass). Each participating center’s institutional review board
approved the VIBRANT study protocol. From October
2005 to December 2007, patients undergoing evaluation
for endovascular treatment of symptomatic SFA occlusive
disease were screened for trial participation. The study
protocol was reviewed with each potential patient, and
written informed consent was obtained. The study was
registered on ClinicalTrials.gov (NCT00228384).All study candidates reported claudication symptoms
and/or ischemic rest pain, with or without minor ischemic
tissue loss (Rutherford categories 1-5),7 corroborated by
demonstration of an ankle-brachial index (ABI) of # 0.9
in the symptomatic limb. Anatomic inclusion criteria
included the presence of de novo atherosclerosis or >6
months post-percutaneous transluminal angioplasty (PTA)
disease of the SFA with stenosis and/or occlusion $8 cm
in length (consistent with TASC I class C and D lesions),
Table III. Lesion and anatomic characteristics
VIABAHN
stent graft
Bare nitinol
stent P valuea
Number of randomized
subjects
72 76
Location of lesion within
the SFA
No. (data available) 72 76
Proximal 31 (43.1%) 33 (43.4%) 1.000
Mid 59 (81.9%) 64 (84.2%) .827
Distal 56 (77.8%) 60 (78.9%) 1.000
Type of lesion .619
No. (data available) 72 76
Stenosis 28 (38.9%) 33 (43.4%)
Occlusion 44 (61.1%) 43 (56.6%)
Target lesion length (cm) .867
No. (data available) 72 76
Mean (SD) 19 (8) 18 (7)
Median 20 16
Range (8-40) (8-36)
Lesion calciﬁcation .009
No. (data available) 72 76
None 14 (19.4%) 11 (14.5%)
Mild 13 (18.1%) 33 (43.4%)
Moderate 31 (43.1%) 24 (31.6%)
Severe 14 (19.4%) 8 (10.5%)
Tibial runoff .104
No. (data available) 72 76
1 vessel 11 (15.3%) 17 (22.4%)
2 vessels 36 (50.0%) 25 (32.9%)
3 vessels 25 (34.7%) 34 (44.7%)
SD, Standard deviation; SFA, superﬁcial femoral artery.
aP values for continuous measures based on Wilcoxon test with pooled
variances; for categorical variables on two-tailed Fisher exact test
(comparing VIABAHN stent graft and bare nitinol stent).
Table IV. Technical success
VIABAHN
Bare nitinol
stent P valuea
Number of enrolled
subjects
72 76
Overall technical success 1.000
No. (data available) 69 69
Yes 67 (97.1%) 66 (95.7%)
No 2 (2.9%) 3 (4.3%)
Maximum stenosis
following stent
deployment <30%
1.000
No. (data available) 72 76
Yes 71 (98.6%) 74 (97.4%)
No 1 (1.4%) 2 (2.6%)
Final hemodynamic peak
gradient #15 mm Hg
1.000
No. (data available) 69 69
Yes 68 (98.6%) 68 (98.6%)
No 1 (1.4%) 1 (1.4%)
Device(s) successfully
delivered to cover
target lesion
1.000
No. (data available) 72 76
Yes 72 (100.0%) 76 (100.0%)
No 0 (0.0%) 0 (0.0%)
aP values derived from Fisher exact test.
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cm of the SFA, and the popliteal artery beginning 5 cm
above the radiographic knee joint line. Unobstructed runoff
to the level of the ankle was documented, consisting of
a patent popliteal artery and at least one tibial artery. Vessel
reference diameters were appropriate to the use of 6-, 7-, or
8-mm diameter stents or stent grafts. Because of a lack of
FDA approval at the time of the study, 5-mm-diameter
and heparin-bonded VIABAHN stent grafts were not used.
Primary end points. The efﬁcacy end point of the
study was primary patency at 3 years postprocedure. Loss
of primary patency was deﬁned as the ﬁrst occurrence of
any of the following: ultrasound demonstrating peak
systolic velocity ratio (PSVR) >2.0 or occlusion within
the treated arterial segment, angiography with >50%
stenosis or occlusion within the treated arterial segment,
a target lesion revascularization (TLR), or a surgical bypass.
DUS-derived PSVR >2.0 was indicative of >50% resteno-
sis. Lesions occurring within 5 mm of the proximal or distal
ends of the stented segment (“edge stenoses”) were
considered to be part of the treated arterial segment for
analytic purposes. The safety end point was a composite
of procedural (30-day) major adverse events, including
death, myocardial infarction, acute renal insufﬁciency, and
signiﬁcant access site and procedural complications that
required surgical intervention or blood transfusion.Secondary end points. Secondary end points of the
study included additional patency measures, technical
success, hemodynamics, ischemic symptom classiﬁcation,
generic and disease-speciﬁc quality-of-life instrument
reporting, and stent fracture assessment.
In addition to the primary patency end point, primary-
assisted patency and secondary patency were tracked for
the duration of the study. Loss of primary-assisted patency
was deﬁned as the ﬁrst occurrence of any of the following:
ultrasound or angiography demonstrating occlusion of the
treated arterial segment or surgical bypass of the treated arte-
rial segment. Loss of secondary patency was deﬁned as the
ﬁrst occurrence of any of the following: ultrasound or angi-
ography demonstrating occlusion of the treated arterial
segment and no subsequent intervention successfully re-
established blood ﬂow in that arterial segment, or surgical
bypass of the treated arterial segment. The DUS-derived
PSVR>2.0 criterion provides a noninvasive proxy for angio-
graphic 50% restenosis of the femoropopliteal segment, but
the relationship of less stringent PSVR criteria to stent, and
stent graft patency was not fully understood. To explore this
relationship, primary patency outcomes were additionally
stratiﬁed by less stringent criteria, utilizing PSVR cutoffs of
2.5 and 3.0. Technical (procedural) success was deﬁned as
appropriate device deployment with <30% residual stenosis
of the treated arterial segment and #15 mm Hg transle-
sional peak pressure gradient at procedural completion.
ABI values were recorded prior to intervention and at 1,
6, 12, 24, and 36 months postprocedure. Ischemic symp-
toms were stratiﬁed by Rutherford category, and both
the generic short-form 36 (SF-36) questionnaire and
disease-speciﬁc intermittent claudication questionnaire
Table V. Subject status
VIABAHN stent graft, No. (%) Bare nitinol stent, No. (%) Overall, No. (%)
Subjects randomized 72 76 148
Final subject status 72 (100) 76 (100) 148 (100)
Completed study 43 (59.7) 47 (61.8) 90 (60.8)
Surgical intervention 5 (6.9) 5 (6.6) 10 (6.8)
Withdrawn 9 (12.5) 10 (13.2) 19 (12.8)
Lost to follow-up 6 (8.3) 10 (13.2) 16 (10.8)
Death 9 (12.5) 3 (3.9) 12 (8.1)
Other 0 (0.0) 1 (1.3) 1 (0.7)
Fig 1. Primary patency (peak systolic velocity ratio [PSVR] # 2.0).
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Device fractures were determined by independent core
laboratory review of multiplanar radiographs obtained at
12, 24, and 36 months postimplantation (VasCore).
Intervention protocol. Arterial access was obtained
via antegrade ipsilateral or retrograde contralateral femoral
approach. Biplanar angiography of the symptomatic limb
was performed and anatomic inclusion criteria were veri-
ﬁed. On-table randomization to the VIABAHN device or
bare nitinol stent implantation was undertaken after suc-
cessful translesional guidewire passage. The technique and
devices used for crossing total occlusions were left to the
discretion of the treating physician. Systemic intrapro-
cedural anticoagulation was mandatory. Predilation of the
target lesion was accomplished using balloons of nominal
diameter equal to or less than the diameter of the implanted
device. Devices were deployed beginning at the most distal
aspect of disease, and treatment progressed proximally. All
hemodynamically signiﬁcant disease within the SFA, and
all predilated regions were incorporated in the stentedsegment. Where more than one device was required,
overlap zones of 5-10 mm were recommended. Post-
dilation was performed using balloons of nominal diameter
equal to that of the implanted devices, and extension of the
postdilation balloon beyond the margins of the implanted
devices was prohibited. Biplanar completion angiography
and translesional catheter pressure gradient measurements
were used to verify technical success. Arterial closure
devices were used at the discretion of the treating physician.
Medical therapy. Daily aspirin therapy was initiated
prior to intervention. After device implantation and attain-
ment of access site hemostasis, those patients not already
receiving maintenance clopidogrel therapy were given
a 600-mg loading dose. The protocol dictated that study
participants received daily clopidogrel (75 mg) for at least
6 months postprocedure and aspirin (81 mg) until study
completion.
Postimplantation assessments. Follow-up assess-
ments were conducted at 1-, 6-, 12-, 24-, and 36-month
intervals. Each of these evaluations included an examination
Fig 2. Primary-assisted patency.
Fig 3. Secondary patency.
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studies (ABI and DUS), adverse event and Rutherford
category reporting, and completion of the SF-36 and
Intermittent Claudication Questionnaires under the
direction of the study coordinator. Laboratory testing for
serum creatinine was obtained at the 1-month visit, and
radiographs for stent integrity assessment were obtained
at 12, 24, and 36 months.Statistical analyses. Patency rates/estimates were
determined using Kaplan-Meier analysis. Log-rank test
was used to compare patency estimates when patency end
points were stratiﬁed. Discrete values were expressed
as frequencies and percentages using the data available as
the denominator or as noted. Continuous values were
expressed as means (6 standard deviation), along with the
median, and range. For comparative analyses, a P value of
Table VI. ABI: pre- and postintervention
VIABAHN stent graft P valuea Bare nitinol stent P valuea
Number of enrolled subjects 72 76
Preprocedure visit ABI
No. (data available) 67 71
Mean (SD) 0.64 (0.15) 0.67 (0.16)
Median 0.63 0.66
Range (0.33-1.10) (0.18-1.21)
1-month visit ABI <.001 <.001
No. (data available) 68 69
Mean (SD) 1.01 (0.14) 1.01 (0.14)
Median 1.01 1.00
Range (0.59-1.39) (0.53-1.38)
6-month visit ABI <.001 <.001
No. (data available) 62 66
Mean (SD) 0.94 (0.16) 0.94 (0.17)
Median 0.97 0.95
Range (0.25-1.19) (0.44-1.53)
12-month visit ABI <.001 <.001
No. (data available) 63 63
Mean (SD) 0.92 (0.17) 0.93 (0.18)
Median 0.97 0.96
Range (0.43-1.23) (0.31-1.25)
24-month visit ABI <.001 <.001
No. (data available) 50 53
Mean (SD) 0.94 (0.16) 0.94 (0.20)
Median 0.94 0.98
Range (0.56-1.46) (0.38-1.23)
36-month visit ABI <.001 <.001
No. (data available) 46 44
Mean (SD) 0.95 (0.18) 0.97 (0.16)
Median 0.97 0.99
Range (0.47-1.47) (0.55-1.25)
ABI, Ankle-brachial index; SD, standard deviation.
aP values obtained from two-tailed Wilcoxon test with pooled variances of the preprocedure visit and each respective visit interval.
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difference. All statistical analyses were done with SAS
software, v. 9.2 (SAS Institute, Cary, NC).
RESULTS
Demographics, medical history, and arteriographic
ﬁndings. One hundred forty-eight patients elected to
participate in the trial and underwent on-table randomi-
zation. Seventy-six patients were randomly assigned to bare
nitinol stent implantation, and 72 were assigned to VIA-
BAHN endoprosthesis implantation. Patient demographics
and medical history (Table II) were largely similar between
study arms, although patients receiving the VIABAHN
device were signiﬁcantly older than those receiving bare
nitinol stents. Lesion and anatomic characteristics of the
two study groups are displayed in Table III.
Acute procedural outcomes: procedural success and
30-day safety end point. Procedural success, deﬁned as
successful device deployment with less than 30% residual
stenosis, was achieved inmore than 97% of study participants
(Table IV). There were no periprocedural deaths, and
freedom from periprocedural safety events was achieved in
98.6% of VIABAHN recipients and 100% of bare nitinol
stent recipients. The single safety event recorded was an
access-site complication that occurred in the VIABAHNstudy arm. That event was a non-study limb thrombosis that
occurred 2 days after the index procedure and required
surgical intervention. Contralateral arterial access was
utilized in 64/72 (88.9%) Viabahn implantations and in
72/76 (94.7%) bare nitinol stent implantations. In each
study arm, a median of two devices were implanted.
Loss to follow-up. The VIBRANT trial followed
patients for 3 years. Substantial participant attrition accu-
mulated throughout follow-up, with only 60.8% of en-
rollees completing 3 years of postprocedural surveillance.
Table V details the speciﬁc causes of subject attrition. None
of the 12 late participant deaths were determined to be
device or study related.
Patency rates. The primary end point of theVIBRANT
trial was primary patency of the treated arterial segment at
3 years postprocedure, determined by PSVR #2.0, no
occlusion on surveillance DUS, and no TLR. There was
no signiﬁcant difference between 3-year primary patency
for the VIABAHN device (24.2%; 95% conﬁdence interval
[CI], 12.2%-38.5%) or bare nitinol stent (25.9%; 95% CI,
10.3%-45.0%; P ¼ .392), as shown in Fig 1.
Primary-assisted patency and secondary patency were
also evaluated over the course of the study. At the 3-year
end point, bare nitinol stents demonstrated a statistical ad-
vantage over the VIABAHN endoprostheses with regard to
Table VII. Rutherford clinical category: pre- and postintervention
VIABAHN stent graft P valuea Bare nitinol stent P valuea
Number of enrolled subjects 72 76
Preprocedure Rutherford category
No. (data available) 72 75
Mean (SD) 2.7 (0.6) 2.8 (0.8)
Median 3 3
Range (2-5) (1-5)
1-month visit Rutherford category <.001 <.001
No. (data available) 67 72
Mean (SD) 0.6 (1.0) 0.4 (0.9)
Median 0 0
Range (0-5) (0-5)
6-month visit Rutherford category <.001 <.001
No. (data available) 62 71
Mean (SD) 0.7 (1.0) 0.9 (1.0)
Median 0 1
Range (0-4) (0-3)
12-month visit Rutherford category <.001 <.001
No. (data available) 67 71
Mean (SD) 0.8 (1.1) 0.9 (1.2)
Median 0 0
Range (0-4) (0-4)
24-month visit Rutherford category <.001 <.001
No. (data available) 51 59
Mean (SD) 0.8 (1.1) 0.7 (1.1)
Median 0 0
Range (0-4) (0-4)
36-month visit Rutherford category <.001 <.001
No. (data available) 45 49
Mean (SD) 0.9 (1.0) 0.6 (0.9)
Median 1 0
Range (0-3) (0-3)
SD, Standard deviation.
aP values obtained from two-tailed Wilcoxon test with pooled variances of the preprocedure visit and each respective visit interval.
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bare nitinol vs 69.8%; 95% CI, 53.5%-81.3% for the VIA-
BAHN stent graft; P ¼ .04; Fig 2). No signiﬁcant dif-
ferences in 3-year secondary patency were observed
between study arms (89.3%; 95% CI, 77.7%-95.1% for
bare nitinol vs 79.5%; 95% CI, 62.6%-89.4% for the VIA-
BAHN endograft; P ¼ .304; Fig 3).
Effect of alternate PSV ratio end points. Because of
inconsistencies in end point deﬁnitions in the available liter-
ature, we chose to examine the use of less stringent PSV
ratios as ultrasound determinants of loss of primary patency.
Selection of the alternative PSV > 2.5 and PSV > 3.0
criteria resulted in predictable stepwise increases in 3-year
primary patency rates in both study arms (Figs 4 and 5,
online only, respectively), without inducing signiﬁcant dif-
ferences between groups.
Hemodynamic and clinical status improvement.
Following intervention, ankle-brachial indices (Table VI)
improved signiﬁcantly in both treatment arms, and this
improvement was sustained throughout the duration of the
study. There were no signiﬁcant differences noted in mean
ABI values between study groups. In similar fashion,
immediate postintervention Rutherford Clinical Category
scores7 were signiﬁcantly improved from baseline values,
and the reduction in symptomatic status was sustainedthroughout the trial, with no signiﬁcant differences be-
tween treatment arms (Table VII).
Quality-of-life measures. Quality-of-life data were
collected using the disease-speciﬁc ICQ and the more
generic SF-36 instrument. A decline in ICQ scores indi-
cates a favorable response, whereas an increased SF-36
score indicates improvement in the relevant domain. ICQ
scores improved (declined) postprocedure, and this was
a durable ﬁnding at each successive surveillance interval
(Table VIII, online only). A similar pattern was noted for
SF-36 physical domain scores, where an immediate and
durable improvement (increased score) was noted fol-
lowing intervention (Table IX, online only).
Medication. Clopidogrel compliance through 6
months postintervention was documented in 78.7% of
VIABAHN recipients and 83.6% of bare nitinol stent recip-
ients (P ¼ NS). At the 36-month study completion visit, all
but 1/44 (2.3%) VIABAHN and 2/46 (4.3%) bare nitinol
stent recipients were receiving monotherapy or some
combination of aspirin, clopidogrel, or other anticoagulant.
Repeat interventions. There was no signiﬁcant differ-
ence in either overall reintervention rates (Table X) or
Kaplan-Meier estimates of freedom from initial reinter-
vention (Fig 6) between study arms. Technique of rein-
tervention was left to the discretion of the treating
Fig 6. Freedom from ﬁrst reintervention.
Table X. Reinterventions (TLRs)
VIABAHN,
No. (%)
Bare nitinol
stent,
No. (%)
Combined,
No. (%)
P
valuea
Subjects available 72 76 148
Repeat
interventions
per subjecta
.801
0 47 (65.3) 50 (65.8) 97 (65.5)
1 17 (23.6) 16 (21.1) 33 (22.3)
2 4 (5.6) 7 (9.2) 11 (7.4)
3 3 (4.2) 1 (1.3) 4 (2.7)
4 1 (1.4) 1 (1.3) 2 (1.4)
5 0 (0.0) 0 (0.0) 0 (0.0)
6 0 (0.0) 1 (1.3) 1 (0.7)
7 0 (0.0) 0 (0.0) 0 (0.0)
8 0 (0.0) 0 (0.0) 0 (0.0)
TLR, Target lesion revascularization.
aP value obtained from comparison of total reinterventions for VIABAHN
and bare nitinol stent groups using Fisher exact test.
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rence, as well as the types of interventions employed in
these TLRs, are shown in Table XI. Use of more than one
technique (angioplasty, additional stent deployment, etc)
to achieve successful TLR was common.
Fractures. Fractures were signiﬁcantly more common
in the bare nitinol stent arm, and these fractures were
strongly associated with the stented lesion length
(Table XII, online only). Furthermore, fracture severity
was signiﬁcantly greater for bare nitinol stents than for
VIABAHN endoprostheses (Table XIII, online only).
Limb status. There were no instances of major ampu-
tation (transtibial or proximal) among study participants in
either treatment arm.
DISCUSSION
The VIBRANT trial provides long-term outcomes for
the endovascular treatment of complex atherosclerotic
SFA lesions (TASC I class C and D).1 The data from
this multicenter, randomized trial demonstrate that expert
interventionists can successfully perform percutaneous
revascularization of long-segment, predominantly oc-
cluded SFA lesions with commendable procedural safety.
Per the trial design, subjects were randomized after
successful wire traversal of the study lesions; this departure
from intent-to-treat study design precludes direct compar-
ison of these results with surgical bypass. Although the
study end point of primary patency at 3 years was disap-
pointingly low, primary-assisted and secondary patency
rates were substantially greater. Durable improvements
in hemodynamic measures and clinical status were noted,
and quality-of-life instruments, in particular the disease-speciﬁc Intermittent Claudication Questionnaire, dis-
played immediate and sustained improvement following
intervention. Finally, no study patient required major
amputation during the course of the trial. Thus, at 3
years, substantially equivalent safety and efﬁcacy were
demonstrated between the VIABAHN endograft and
bare nitinol stent treatment arms.
Does a rigorous postintervention program of clinical
and DUS surveillance, as employed in the VIBRANT trial,
favorably affect outcomes of percutaneous SFA interven-
tion? The question cannot be answered deﬁnitively herein,
as all study participants were assigned to mandatory follow-
Table XI. TLR time frame and techniques
VIABAHN,
No. (%)
Bare
nitinol stent,
No. (%)
P
value
Subjects randomized 72 76
Subjects having a TLRa 25 (34.7) 26 (34.2) 1.000
Time frame of earliest TLRb
0-45 days postimplant 0 (0.0) 0 (0.0)
>45-90 days postimplant 0 (0.0) 1 (3.8)
>90-180 days postimplant 4 (16.0) 2 (7.7)
>180-365 days postimplant 8 (32.0) 12 (46.2)
>365-730 days postimplant 8 (32.0) 8 (30.8)
>730-1096 days postimplant 5 (20.0) 3 (11.5)
>1096 days postimplant 0 (0.0) 0 (0.0)
TLRs performedb
Total TLRs 38 43
Balloon angioplasty 31 (81.6) 37 (86.0)
Thrombolysis 8 (21.1) 11 (25.6)
Mechanical thrombectomy
(Angiojet)
14 (36.8) 13 (30.2)
Deployment of an
additional stent/stent
graft
22 (57.9) 21 (48.8)
Bare nitinol stentc 10 (45.5) 4 (19.0)
Stent graftc 11 (50.0) 17 (81.0)
Other 6 (15.8) 5 (11.6)
TLR, Target lesion revascularization.
aP value obtained from two-tailed Fisher exact test of VIABAHN and bare
nitinol stent.
bP values are not provided due to the limited observations per group and the
lack of statistical power to detect a true difference between treatment
groups.
cPercentage out of the number of subjects with additional devices deployed.
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participants underwent reintervention during the 3 years
of postimplant surveillance, and multiple reinterventions
were required in some instances. These secondary proce-
dures are most easily undertaken prior to complete throm-
bosis of the treated arterial segment. While the optimal
interval between surveillance examinations has not been
deﬁned, detection and timely treatment of restenosis likely
contributed to the admirable assisted patency rates, durable
clinical beneﬁt, and complete limb preservation experi-
enced by VIBRANT participants.
The VIBRANT trial design differed substantially from
the majority of endovascular femoropopliteal intervention
studies. At the outset of this study, planned trial duration
of 3 years exceeded current norms, and treatment of
lesion lengths with no upper limit remained to be attemp-
ted. In addition, rigorous comparison of two nonangioplasty
modalities in infrainguinal trials remains a rarity. Comparison
to PTA was (and remains) the de facto standard for estab-
lishing clinical safety and efﬁcacy of newer modalities for
SFA treatment. Yet the FDA’s imprimatur for clinical trials
that utilize the Vascular InterVentional Advances (VIVA)
Physicians Objective Performance Criteria for SFA stents12
indicates acceptance of the premise that bare nitinol stents
deliver 1-year patency rates far in excess of those achieved
with PTA, consistent with data derived from trials by
Schillinger and others.13-15 While PTA provides a static,if inferior, comparator for device approval purposes,
robust comparisons between nonangioplasty-based strate-
gies provide vital information for practitioners addressing
complex SFA disease.
Several weaknesses of the current study deserve mention.
In retrospect, VIBRANT would have been strengthened by
the incorporation of a physical functioning end point.16,17
Future trials would beneﬁt from addition of a supervised-
exercise rehabilitation comparison arm.18 Over 3 years of
surveillance, attrition rates were substantial, albeit similar
between treatment groups. Device iterations progress as clin-
ical trials are conducted, but the pace of innovation should
not deter physicians from engaging in careful evaluation of
each generation of devices.
Since the study completion, there have been multiple
manufacturing changes to the VIABAHN device, includ-
ing addition of a heparin bioactive surface, a contoured
proximal edge, and an SFA treatment indication for the
5-mm-diameter device. In addition, bare nitinol stents
with improved ﬂexibility have been released to market,
which may reduce the incidence of stent fracture, although
these new devices await evaluation in complex lesions
comparable to the VIBRANT trial.
In conclusion, the VIBRANT trial evaluated the com-
parative effectiveness of bare nitinol stents vs VIABAHN
stent grafts for the treatment of complex SFA atheroscle-
rosis. Primary patency rates for the two study arms were
similarly low at the 3-year trial end point, but scheduled
surveillance and judicious reintervention resulted in sus-
tained hemodynamic and symptomatic improvement in
both treatment groups.
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APPENDIX. VIBRANT Site Investigators
David Lasorda, DO, AlleghenyGeneralHospital, Pittsburgh,
Pa;Michael Rush,MD,HolyCrossHospital, Ft. Lauderdale,
Fla; Jeffrey Goldstein, MD, St. Johns, Springﬁeld, Ill; Bob
Smouse, MD, St. Francis, Peoria, Ill; Manju Kalra, MD,
Mayo Clinic, Rochester, Minn; Sean Lyden, MD, Cleveland
Clinic, Cleveland, Ohio; R. Andrew Blum, MD, Midwest
Heart Foundation,Lombard, Ill;ArunChervu,MD,Vascular
SurgicalAssociates,Austell,Ga;WilliamGray,MD,Columbia
University Medical Center, New York, NY; Romi Chopra,
MD, Midwest Institute, Melrose Park, Ill; Sam Money,
MD,MayoClinic, Scottsdale,Ariz;DavidMego,MD,Arkan-
sas Heart, Little Rock, Ark; Mark Bates, MD, Charleston
Medical Center, WVa; Richard Begg, MD, Heritage Valley
Health System, Beaver Falls, Pa; Barry Katzen, MD, Baptist
Cardiac and Vascular Institute, Miami, Fla; W. Charles
Sternbergh, MD, Ochsner Clinic, New Orleans, La.INVITED COMMENTARYMagruder C. Donaldson, MD, Boston, MassThe strengths of this multicenter prospective trial comparing
bare nitinol stents to polytetraﬂuoroethylene stent grafts for Trans-
Atlantic Inter-Society Consensus 1 C and D superﬁcial femoral
artery lesions include an uncommon effort to standardize method-
ology and an uncommon glimpse at 3-year outcomes. The inves-
tigators are to be commended for attempting to drive a guidepost
into the riverbed and refusing to go with the ﬂow, simply assuming
that any decent study will be outdated by intercurrent innovations
such as drug-eluting stents and heparin-bonded stent grafts.
The study tests the reasonable hypothesis that covered stents
would eliminate in-stent restenosis, a chief cause of nitinol stent
failure. Though the patency comparisons at 3 years suffer from
some attrition of patients with cautionary wobble in the Kaplan-
Meier curves, there was no apparent patency advantage to stent
grafts. The reader remains intrigued by the lack of details regarding
the ultrasound and angiographic lesions responsible for device
failure, which given the surveillance protocol and high rate of rein-
tervention, must have been available to allow distinction between
intimal hyperplasia at the stent margins or within the stents and
progression of disease in untreated adjacent arterial segments.
Among patients followed for 36 months, the stent fracture rate
was 50% for nitinol stents and only 2% for stent grafts.Acknowledging that the impact of stent fracture is controversial,
if one assumes a negative impact of fracture on nitinol stent
patency and a positive impact of less in-stent restenosis on stent
graft patency, we might have expected an unequivocal patency
advantage for stent grafts rather than the somewhat disappointing
equivalency between the two groups. If indeed nitinol stents and
stent grafts do have similar efﬁcacy, device cost would assume
more importance in the current penny-pinching era.
Comparison of trial results with surgical bypass is invalidated
by randomization of patients only after lesions had been crossed
by a guidewire. Nonetheless, optimal results at 3 years were
attained only after one or more reinterventions in 40% of patients,
a much higher rate than might be expected in a series of superﬁcial
femoral artery bypasses. Again, costs need consideration.
The study employed somewhat confusing patency deﬁnitions
unfamiliar to most surgeons accustomed to tracking bypass grafts.
Development of standards for reporting has been one of the signal
contributions to vascular surgery over the years, and we must
extend this effort to the endovascular arena, including our
colleagues in related subspecialties. Only by adopting uniform
research methodology can we build fruitfully on earnest efforts
such as those of the VIBRANT trial team.
Fig 4 (online only). Primary patency using alternate criterion of peak systolic velocity ratio (PSVR) # 2.5.
Fig 5 (online only). Primary patency using alternate criterion of peak systolic velocity ratio (PSVR) # 3.0.
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Table VIII (online only). Quality of life: intermittent claudication questionnaire scores
VIABAHN P valuea Bare nitinol stent P valuea
Number of enrolled subjects 72 76
Preprocedure visit ICQ score
No. (data available) 72 75
Mean (SD) 46.6 (20.1) 50.1 (18.2)
Median 46 55
Range (8-91) (8-80)
1-month visit ICQ score <.001 <.001
No. (data available) 66 72
Mean (SD) 17.2 (15.7) 20.5 (18.7)
Median 12 14
Range (0-58) (0-68)
6-month visit ICQ score <.001 <.001
No. (data available) 57 66
Mean (SD) 27.2 (25.8) 23.1 (20.8)
Median 20 18
Range (0-91) (0-66)
12-month visit ICQ score <.001 <.001
No. (data available) 53 62
Mean (SD) 25.6 (21.3) 23.5 (20.3)
Median 23 22
Range (0-72) (0-85)
24-month visit ICQ score <.001 <.001
No. (data available) 44 51
Mean (SD) 23.9 (19.3) 20.5 (18.7)
Median 19 17
Range (0-66) (0-66)
36-month visit ICQ score <.001 <.001
No. (data available) 40 45
Mean (SD) 20.8 (19.6) 22.9 (21.2)
Median 17 20
Range (0-71) (0-82)
ICQ, Intermittent claudication questionnaire; SD, standard deviation.
aP value obtained from two-tailed Wilcoxon test with pooled variances of the preprocedure visit and each respective visit interval.
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Table IX (online only). Quality of life: SF-36 questionnaire scores (physical domain)
VIABAHN stent graft P valuea Bare nitinol stent P valuea
Number of enrolled subjects 72 76
Preprocedure visit SF-36 physical score
No. (data available) 71 74
Mean (SD) 33.6 (9.9) 32.9 (8.5)
Median 33 33
Range (14-59) (14-51)
1-month visit SF-36 physical score <.001 <.001
No. (data available) 66 72
Mean (SD) 42.2 (10.2) 41.4 (10.8)
Median 43 42
Range (19-59) (12-59)
6-month visit SF-36 physical score <.001 <.001
No. (data available) 57 66
Mean (SD) 40.4 (11.1) 40.3 (10.4)
Median 42 41
Range (22-56) (18-58)
12-month visit SF-36 physical score .001 <.001
No. (data available) 52 62
Mean (SD) 40.5 (11.7) 39.8 (10.7)
Median 40 39
Range (17-60) (19-59)
24-month visit SF-36 physical score .004 <.001
No. (data available) 43 48
Mean (SD) 39.8 (11.5) 40.6 (10.9)
Median 38 40
Range (15-61) (19-62)
36-month visit SF-36 physical score <.001 .005
No. (data available) 39 45
Mean (SD) 41.9 (11.7) 38.7 (10.5)
Median 45 37
Range (21-61) (16-59)
SD, Standard deviation; SF, short form.
aP values obtained from two-tailed Wilcoxon test with pooled variances of the preprocedure visit and each respective visit interval.
Table XII (online only). Stent fractures by stented length
VIABAHN stent graft Bare nitinol stent P valuea
Number of enrolled subjects 72 76
Stent fractures at 12-month visit <.001
No. (data available)b 47 55
Yesc 1 (2.1%) 18 (32.7%)
Stented length 0-15 cm 1 (11.1%)/9 0 (0.0%)/10
Stented length 16-25 cm 0 (0.0%)/16 8 (29.6%)/27
Stented length 26þ cm 0 (0.0%)/22 10 (55.6%)/18
No 46 (97.9%) 37 (67.3%)
Stent fractures at 24-month visit <.001
No. (data available)b 43 47
Yesc 2 (4.7%) 23 (48.9%)
Stented length 0-15 cm 2 (28.6%)/7 0 (0.0%)/11
Stented length 16-25 cm 0 (0.0%)/16 11 (52.4%)/21
Stented length 26þ cm 0 (0.0%)/20 12 (80.0%)/15
No 41 (95.3%) 24 (51.1%)
Stent fractures at 36-month visit <.001
No. (data available)b 38 42
Yesc 1 (2.6%) 21 (50.0%)
Stented length 0-15 cm 1 (14.3%)/7 1 (11.1%)/9
Stented length 16-25 cm 0 (0.0%)/14 12 (54.5%)/22
Stented length 26þ cm 0 (0.0%)/17 8 (72.7%)/11
No 37 (97.4%) 21 (50.0%)
aData limited to diagnostic quality x-rays. P value obtained from two-tailed Fisher exact test of VIABAHN stent graft and bare nitinol stent.
b12-, 24-, and 36-month X-rays are limited to those performed between 274-548, 549-913, and 914-1270 days since procedure, respectively.
cDenominator for percentages is the number of subjects available per visit window.
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Table XIII (online only). Stent fracture severity classiﬁcation
VIABAHN Bare nitinol stent P valuea
Number of enrolled subjects 72 76
Stent fractures at 12-month visit <.001
No. (data available)b 47 55
Yesc 1 (2.1%) [1] 18 (32.7%) [24]
Grade 1 - Single strut 1 (2.1%) [1] 7 (12.7%) [8]
Grade 2 - Multiple struts 0 (0.0%) [0] 8 (14.5%) [10]
Grade 3 - Fracture without separation 0 (0.0%) [0] 3 (5.5%) [3]
Grade 4 - Fracture with separation 0 (0.0%) [0] 3 (5.5%) [3]
No 46 (97.9%) 37 (67.3%)
Stent fractures at 24-month visit <.001
No. (data available)b 43 47
Yesc 2 (4.7%) [2] 23 (48.9%) [32]
Grade 1 - Single strut 2 (4.7%) [2] 10 (21.3%) [12]
Grade 2 - Multiple struts 0 (0.0%) [0] 10 (21.3%) [12]
Grade 3 - Fracture without separation 0 (0.0%) [0] 2 (4.3%) [2]
Grade 4 - Fracture with separation 0 (0.0%) [0] 6 (12.8%) [6]
No 41 (95.3%) 24 (51.1%)
Stent fractures at 36-month visit <.001
No. (data available)b 38 42
Yesc 1 (2.6%) [1] 21 (50.0%) [25]
Grade 1 - Single strut 1 (2.6%) [1] 8 (19.0%) [8]
Grade 2 - Multiple struts 0 (0.0%) [0] 10 (23.8%) [12]
Grade 3 - Fracture without separation 0 (0.0%) [0] 2 (4.8%) [2]
Grade 4 - Fracture with separation 0 (0.0%) [0] 3 (7.1%) [3]
No 37 (97.4%) 21 (50.0%)
The values listed indicate the number of subjects experiencing a stent fracture, whereas the number in brackets indicates the total number of fractures,
including multiple stent fractures per subject.
aP value obtained from two-tailed Fisher exact test of VIABAHN and bare nitinol stent.
bAvailability limited to subjects with a diagnostic quality x-ray.
cThe sum of individual grades may be greater than the number of subjects experiencing a stent fracture, for subjects can have multiple-grade stent fractures.
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